The new antiasthm atic combined long-acting drug — combipec
Abstract
The clinical effectivity of the new long-acting bronchodilator consisting of theophylline and sulbutamol in the form of a tablet with a special polymer carrier was investigated. Therapeutic effects of combipec were evaluated by clinical and instrumental methods before and on the 2nd, 7th, 14th, 21st and 28th day of treatment. The results of lung function testing reliably increase in comparison with the results before treatment. Data indicate that combipec has a high clinical effect and minimazes the use of other drugs. Adverse reactions were minimal and were over by themselves without additional medicines.
About the Authors
A. G. Chuchalin
РГМУ
Russian Federation
Russian Federation
V. A. Kemenova
РГМУ
Russian Federation
Russian Federation
S. A. Bulgakov
РГМУ
Russian Federation
Russian Federation
S. M. Mydani
РГМУ
Russian Federation
Russian Federation
References
1. Чучалин А. Г., Д аниляк И. Г., Барвиченко Л. И., Кеменова В. А., Кукес В. Г., Лебедин Ю. С. Теофиллины пролонгированного действия в терапии бронхиальной астмы / / Тер. арх.— 1989.— № 8.— С. 30—37.
2. Advances in Terbulatine Pharmacokinetics / Eds L. Nyberg, C. Wood.— Copenhagen: Munksgaard, 1984.
3. Anti-Asthma Xanthines and Adenosine / Ed. K.-E. Anderson.— Amsterdam: Excerpta med., 1985.
Review
For citations:
Chuchalin A.G., Kemenova V.A., Bulgakov S.A., Mydani S.M. The new antiasthm atic combined long-acting drug — combipec. PULMONOLOGIYA. 1992;(3):54-58. (In Russ.)
Views:
155
Email this article 